How a Cell Therapy Site Restored Execution Stability and Eliminated a Deviation Backlog Without Adding Headcount

Client name and certain operational details have been modified to preserve confidentiality while maintaining the integrity of the operational outcomes described.

Executive Snapshot

A growing deviation investigation backlog at a cell-therapy CDMO had reached a breaking point.

More than 50 deviation investigations remained unresolved. Batch disposition had slowed to a standstill. Client confidence was deteriorating, and clinical product could no longer move toward release.

GMPKit was engaged to stabilize the investigation process, restore operational throughput, and help reopen the clinical disposition pipeline.

By the conclusion of the engagement, the backlog was eliminated, client confidence had stabilized, the disposition pipeline was restored, and clinical supply resumed.

Following recovery, client leadership estimated that the restoration of operations, lot release activities, and accelerated project closeout generated more than $3.5 million in combined operational and financial impact.

Clinical Supply Had Stopped

Cascadia Therapeutics (fictional name), a cell therapy CDMO supporting clinical manufacturing operations, faced a growing deviation investigation backlog that had disrupted normal operational flow across manufacturing, quality, and client review functions.

More than 50 unresolved manufacturing-related deviations had accumulated across the site. Investigations repeatedly cycled through review and rework, while batch disposition activity slowed further with each escalation.

The organization’s client no longer had confidence in the investigation process. Clinical product became tied up in disposition workflows, creating operational pressure across both organizations and increasing the risk of clinical supply disruption.

What initially appeared to be a quality backlog had evolved into a broader execution stability problem.

Operational Diagnosis: The Deviation Backlog Was Only the Symptom

The issue was not simply the number of deviations.

The investigation system itself had become overloaded.

Manufacturing teams whose primary responsibility was batch execution carried much of the investigative burden despite limited experience with complex deviation investigation practices. Effective investigations require more than documenting an event—they must establish scope, identify root causes, assess impact, and support meaningful corrective actions. Investigations routinely returned through review cycles with requests for clarification, expanded scope, or additional root cause analysis.

(For readers unfamiliar with the investigation process, GMPKit's article "What Is a GMP Deviation Investigation?" provides additional background.)

As investigations cycled repeatedly through rework:

• operational throughput slowed
• review burden increased
• production pressure intensified
• client escalation activity continued to grow

The organization was consuming hundreds of labor hours managing investigation churn while simultaneously attempting to maintain manufacturing execution.

The operational and financial impact extended far beyond documentation delays. Batch loss exposure, production disruption, labor consumption, remanufacturing activity, and hidden factory costs generated an estimated multi-million-dollar Cost of Poor Quality (COPQ).

The backlog itself was only the visible symptom.

Systemic Overdue Deviations are a Stock to Flow System Challenge

Rather than approaching the engagement as a documentation cleanup effort, GMPKit approached the issue as a broader operational systems problem.

The recovery strategy focused on stabilizing how investigation work entered, moved through, and exited the organization’s operational workflows.

Using a stock to flow metaphor of faucet, sink, and drain, to teach systems analysis in governance, GMPKit enabled the team to evaluate:

• the sources contributing to new investigation inflow
• the operational friction slowing investigation throughput
• the constraints preventing efficient disposition and approval

This systems-thinking approach reframed the challenge from simply “closing deviations faster” to restoring execution control across the investigation lifecycle.

The engagement aligned closely with GMPKit’s broader operational recovery model:

• scope the operational instability
• develop structured recovery actions
• implement targeted execution controls
• sustain performance through governance and operational discipline

Rebuilding the Deviation Investigation Process

GMPKit implemented a structured operational recovery approach focused on improving investigation quality, execution alignment, and governance discipline.

The engagement standardized investigation practices, strengthened cross-functional coordination, and introduced clearer operational controls around investigation execution and review readiness.

GMPKit also applied elements of its structured deviation framework, emphasizing planning, foundational alignment, structured execution, and review readiness before final approval. This framework enables streamlined, faster investigation while improving quality at the same time.

This approach significantly reduced downstream rework caused by unclear scope, inconsistent investigation quality, and misaligned review expectations.

At the same time, GMPKit worked with site leadership to identify recurring sources of operational disruption contributing to investigation inflow.

This dual-focus approach allowed the organization to reduce the backlog while improving overall investigation throughput and review effectiveness.

Deviation Investigation System Stabilization

As investigation quality and operational alignment improved, review cycles accelerated and backlog pressure began to decline.

The organization improved investigation throughput, reduced operational rework, and restored more predictable collaboration between manufacturing, quality, and client stakeholders.

Over time, the batch disposition pipeline reopened, allowing delayed clinical product to move toward release.

The organization:

• eliminated the backlog
• improved investigation throughput
• stabilized client engagement
• restored disposition flow
• resumed clinical product release
• generated more than $3.5 million in combined operational and financial impact, as estimated by client leadership.

Most importantly, patients once again received access to critical therapies that had previously been delayed by operational instability.

Frameworks Demonstrated in This Recovery

This engagement combined several operational concepts that GMPKit routinely applies across GMP manufacturing recovery efforts:

• Cost of Poor Quality (COPQ)
• Execution Stability
• Governance Archetypes
• Hidden Factory Reduction
• Systems Thinking
• Structured Operational Recovery
• Deviation Investigation Governance
• Throughput Stabilization

These concepts work together to help organizations move beyond reactive firefighting and restore operational control across manufacturing and quality operations.

Operational Recovery Requires More Than Documentation

Deviation backlogs are rarely isolated quality problems.

More often, they are indicators of broader operational instability driven by governance gaps, workflow overload, execution friction, and inconsistent operational controls.

Sustainable recovery requires more than closing investigations.

It requires restoring operational control across the execution system itself.

Continue Exploring GMPKit Frameworks

This case study demonstrates how multiple GMPKit operational concepts can work together to stabilize manufacturing operations and restore execution flow.

To explore the underlying concepts further:

• Cost of Poor Quality (COPQ)
• Exponential nature of deviation backlogs
• Execution stability principles
• GMPKit Investigation Blueprint™
• Governance archetypes in GMP operations
• What is a GMP Deviation Investigation?

Or, if your organization is experiencing similar operational friction:

Run the COPQ Calculator

or

Schedule a Discovery Call